CD8A and breast carcinoma: IPA enhances H3K27 acetylation at the Tcf7 super-enhancer, driving CD8+ T cell differentiation toward Tpex cells and improving immune checkpoint inhibitor efficacy in melanoma, breast cancer, and CRC (376).